blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3584241

EP3584241 - METHOD FOR PRODUCING INDAZOLE COMPOUND, AND INDAZOLE COMPOUND [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.03.2024
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  24.03.2023
FormerGrant of patent is intended
Status updated on  02.11.2022
FormerExamination is in progress
Status updated on  12.03.2021
FormerRequest for examination was made
Status updated on  22.11.2019
FormerThe international publication has been made
Status updated on  25.08.2018
Most recent event   Tooltip15.11.2024Lapse of the patent in a contracting state
New state(s): BG		published on 18.12.2024 [2024/51]
Applicant(s)For all designated states
FUJIFILM Corporation
26-30, Nishiazabu 2-chome
Minato-ku
Tokyo 106-8620 / JP
[2023/17]
Former [2021/14]For all designated states
FUJIFILM Corporation
26-30, Nishiazabu 2-chome, Minato-ku
Tokyo 106-8620 / JP
Former [2019/52]For all designated states
FUJIFILM Corporation
26-30, Nishiazabu 2-chome Minato-ku
Tokyo 106-8620 / JP
Inventor(s)01 / TAKAHASHI Motomasa
c/o FUJIFILM CORPORATION
577 Ushijima
Kaisei-machi
Ashigarakami-gun Kanagawa 258-8577 / JP
 [2019/52]
Representative(s)Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
[2019/52]
Application number, filing date18754591.814.02.2018
[2019/52]
WO2018JP04996
Priority number, dateJP2017002525514.02.2017         Original published format: JP 2017025255
[2019/52]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018151126
Date:23.08.2018
Language:JA
[2018/34]
Type: A1 Application with search report 
No.:EP3584241
Date:25.12.2019
Language:EN
[2019/52]
Type: B1 Patent specification 
No.:EP3584241
Date:26.04.2023
Language:EN
[2023/17]
Search report(s)International search report - published on:JP23.08.2018
(Supplementary) European search report - dispatched on:EP11.11.2019
ClassificationIPC:C07D231/56, C07D401/06
[2019/52]
CPC:
C07D231/56 (EP,US); C07D401/04 (US); C07D401/06 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/52]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:VERFAHREN ZUR HERSTELLUNG EINER INDAZOLVERBINDUNG UND INDAZOLVERBINDUNG[2019/52]
English:METHOD FOR PRODUCING INDAZOLE COMPOUND, AND INDAZOLE COMPOUND[2019/52]
French:PROCÉDÉ DE PRODUCTION D'UN COMPOSÉ D'INDAZOLE, ET COMPOSÉ D'INDAZOLE[2019/52]
Entry into regional phase13.08.2019Translation filed 
13.08.2019National basic fee paid 
13.08.2019Search fee paid 
13.08.2019Designation fee(s) paid 
13.08.2019Examination fee paid 
Examination procedure13.08.2019Examination requested  [2019/52]
04.06.2020Amendment by applicant (claims and/or description)
16.03.2021Despatch of a communication from the examining division (Time limit: M04)
20.07.2021Reply to a communication from the examining division
03.11.2022Communication of intention to grant the patent
10.03.2023Fee for grant paid
10.03.2023Fee for publishing/printing paid
10.03.2023Receipt of the translation of the claim(s)
Opposition(s)29.01.2024No opposition filed within time limit [2024/14]
Fees paidRenewal fee
13.02.2020Renewal fee patent year 03
12.02.2021Renewal fee patent year 04
14.01.2022Renewal fee patent year 05
03.01.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT26.04.2023
BG26.04.2023
CZ26.04.2023
DK26.04.2023
EE26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
IT26.04.2023
LT26.04.2023
LV26.04.2023
MC26.04.2023
NL26.04.2023
PL26.04.2023
RO26.04.2023
RS26.04.2023
SE26.04.2023
SI26.04.2023
SK26.04.2023
SM26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
[2024/51]
Former [2024/45]AT26.04.2023
CZ26.04.2023
DK26.04.2023
EE26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
IT26.04.2023
LT26.04.2023
LV26.04.2023
MC26.04.2023
NL26.04.2023
PL26.04.2023
RO26.04.2023
RS26.04.2023
SE26.04.2023
SI26.04.2023
SK26.04.2023
SM26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2024/26]AT26.04.2023
CZ26.04.2023
DK26.04.2023
EE26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
IT26.04.2023
LT26.04.2023
LV26.04.2023
NL26.04.2023
PL26.04.2023
RO26.04.2023
RS26.04.2023
SE26.04.2023
SI26.04.2023
SK26.04.2023
SM26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2024/24]AT26.04.2023
CZ26.04.2023
DK26.04.2023
EE26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
LT26.04.2023
LV26.04.2023
NL26.04.2023
PL26.04.2023
RO26.04.2023
RS26.04.2023
SE26.04.2023
SI26.04.2023
SK26.04.2023
SM26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2024/10]AT26.04.2023
CZ26.04.2023
DK26.04.2023
EE26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
LT26.04.2023
LV26.04.2023
NL26.04.2023
PL26.04.2023
RO26.04.2023
RS26.04.2023
SE26.04.2023
SK26.04.2023
SM26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2024/08]AT26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
LT26.04.2023
LV26.04.2023
NL26.04.2023
PL26.04.2023
RS26.04.2023
SE26.04.2023
SK26.04.2023
SM26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2024/03]AT26.04.2023
ES26.04.2023
FI26.04.2023
HR26.04.2023
LT26.04.2023
LV26.04.2023
NL26.04.2023
PL26.04.2023
RS26.04.2023
SE26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2024/01]AT26.04.2023
ES26.04.2023
HR26.04.2023
LT26.04.2023
LV26.04.2023
NL26.04.2023
PL26.04.2023
RS26.04.2023
SE26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2023/51]AT26.04.2023
ES26.04.2023
HR26.04.2023
NL26.04.2023
PL26.04.2023
RS26.04.2023
SE26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2023/50]AT26.04.2023
ES26.04.2023
NL26.04.2023
PL26.04.2023
SE26.04.2023
NO26.07.2023
GR27.07.2023
IS26.08.2023
PT28.08.2023
Former [2023/48]AT26.04.2023
ES26.04.2023
NL26.04.2023
SE26.04.2023
NO26.07.2023
PT28.08.2023
Former [2023/46]ES26.04.2023
NL26.04.2023
PT28.08.2023
Former [2023/43]NL26.04.2023
Documents cited:Search[XA]WO0102369  (AGOURON PHARMA [US]) [X] 13 * Family member of JP-2003-503481 cited in the International Search Report * [A] 1-12,14,15;
 [XA]WO2004094388  (SIGNAL PHARM LLC [US], et al) [X] 13 * Family member of JP-A-2006-523721 cited in the International Search Report * [A] 1-12,14,15;
 [XA]EP1510516  (EISAI CO LTD [JP]) [X] 13 * Family member of WO-A-03/101968 cited in the International Search Report * [A] 1-12,14,15;
 [XA]EP1650194  (KYOWA HAKKO KOGYO KK [JP]) [X] 13 * Family member of WO-A-2005/012258 cited in the International Search Report * [A] 1-12,14,15;
 [AD]WO2009144554  (PFIZER [US], et al) [AD] 1-15 * Family member of JP-A-2011-521939 cited in the International Search Report *;
 [E]EP3333157  (HARBIN ZHENBAO PHARMACEUTICAL CO LTD [CN], et al) [E] 1-15* Family member of WO-A-2017/024968 cited in the International Search Report *
International search[XA]JP2003503481  [X] 13 * , * [A] 1-12, 14-16;
 [XA]WO03101968  (EISAI CO LTD [JP], et al) [X] 13, 15 * , * [A] 1-12, 14, 16;
 [XA]WO2005012258  (KYOWA HAKKO KOGYO KK [JP], et al) [X] 13 * , 1 15, 12 1 & US 2006/0281789 Al, claims, Table 1, compound 15, EXAMPLE 12, Step 1 & EP 1650194 A1 & CA 2518951 A1 * [A] 1-12, 14-16;
 [XA]WO2005094823  (KYOWA HAKKO KOGYO KK [JP], et al) [X] 13 [A] 1-12, 14-16;
 [XA]JP2006523721  [X] 13 * , * [A] 1-12, 14-16;
 [A]JP2011521939  [A] 1-16 * , [0203]-[0206] & US 2011/0028390 A1, paragraphs [0214]-[0217] & WO 2009144554 A1 & EP 2297163 A1 & CA 2724774 A1 *;
 [XA]WO2016129933  (DAE WOONG PHARMA [KR]) [X] 13-16 * , Claims, 31 Reaction Scheme 2, Examples 62, 134 & EP 3256449 A2 & KR 10-2016-0098909 A & CN 107108517 A * [A] 1-12;
 [PXA]WO2017024968  (MEDSHINE DISCOVERY INC [CN]) [PX] 15 * , 49 & TW 201613928 A *[PA] 1-14, 16;
 [XA]  - LAUFER, RADOSLAW et al., "The Discovery of PLK4 Inhibitors: (E)-3-((lH-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents", Journal of Medicinal Chemistry, (20130000), vol. 56, no. 15, ISSN 0022-2623, pages 6069 - 6087, XP055535331 [X] 13 * , Scheme 2 36, Table 3 51 * [A] 1-12, 14-16

DOI:   http://dx.doi.org/10.1021/jm400380m
 [XA]  - SAMPSON, PETER B. et al., "The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro [cyclopropane-1, 3' [3H] indol] -2' (1'H)-ones as Orally Bioavailable Antitumor Agents", Journal of Medicinal Chemistry, (20150000), vol. 58, no. 1, ISSN 0022-2623, pages 130 - 146, XP055535332 [X] 13 * , Scheme3 (v), 142 14-16 * [A] 1-12, 14-16

DOI:   http://dx.doi.org/10.1021/jm500537u
 [A]  - NORRIS, TIMOTHY et al., "Heavy-Metal-Free Reduction Methodology for Large-Scale Synthesis Applicable to Heterocyclic and Arylhydrazines", Organic Process Research & Development, (20090000), vol. 13, no. 2, ISSN 1083-6160, pages 354 - 357, XP055535334 [A] 1-16 * , Scheme 1 *

DOI:   http://dx.doi.org/10.1021/op8002163
by applicantJP2004514706
 WO2009144554
 JP2016530210
    - Org. Process Res. & Dev., (20140000), pages 266 - 274
    - Org. Process Res. & Dev., (20090000), pages 354 - 357
    - Greene's Protective Groups in Organic Synthesis
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.